BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:04 PM
 | 
Aug 24, 2012
 |  BC Extra  |  Company News

FDA reviewers question Humira benefit in UC

FDA reviewers questioned whether Humira adalimumab from Abbott Laboratories (NYSE:ABT) provides a "clinically meaningful benefit" for ulcerative colitis (UC) patients given the drug's "serious" safety risks and the availability of Remicade infliximab for the indication. Reviewers said Humira provides only a "marginal" effect on induction of remission rates compared to placebo, and a lesser effect on sustained remission rates. The reviewers did say that Humira, which is...

Read the full 329 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >